Академический Документы
Профессиональный Документы
Культура Документы
HIMANSHI
GHOUSIA
PRATEEK
MERGER OF
healthcare company.
GLOBAL HEADQUATERS-UK at GSK House in Brentford, a suburb of west
London, and its US headquarters are in The Navy Yard, Philadelphia and Research
Triangle Park, North Carolina.
OFFICES- over 115 countries
ESTABLISHMENT-2000 (by the merger of Glaxo Wellcome and SmithKline Beecham)
MARKET CAPITALISATION- 79 billion, (as on 2 may 2014)
CEO- Andrew Witty since May 2008.
EMPLOYEES- over 99,000 people, 12,500 of whom work in research and development.
CONTROVERSIES-In July 2012 GSK pleaded guilty to criminal charges and agreed to
a pay $3 billion to settle the criminal charges as well as civil qui tam lawsSuit.
PRODUCTS- drugs and vaccines for major disease areas such as asthma, cancer,
infections, diabetes, digestive and mental health conditions, the biggest selling of
which were Advair, Avodart , Flovent , Augmentina, Lovaza, and Lamictal in
2013. Its drugs and vaccines earned 21.3 billion in 2013.
Top-selling products include its asthma/COPD therapeutics Advair, Ventolin, and
Flovent.
Its consumer healthcare division, which earned 5.2 billion in 2013, sells oral healthcare,
and nutritional products, drinks and over-the-counter medicines,
including Sensodyne, Boost and Horlicks.
The company's over-the-counter health-care products include Abreva to treat cold
sores; Aquafresh, Maclean's and Sensodyne toothpastes; Night Nurse, a cold remedy;
Breathe Right nasal strips. It also sells several drinks, including Horlicks, a malted
milk drink and Boost, a chocolate-flavoured drink.].
GLAXO WELLCOME
Glaxo became Glaxo Laboratories and opened new units in London in 1935.
Glaxo Laboratories bought two companies, Joseph Nathan and Allen &
Hanburys in 1947 and 1958 respectively. After the company bought Meyer
Laboratories in 1978, it started to play an important role in the US market. In
1983 the American arm, Glaxo Inc., moved to Research Triangle Park (US
headquarters/research) and Zebulon (US manufacturing) in North Carolina.
In March 1995 Glaxo and Burroughs Wellcome Co. merged to form Glaxo
Wellcome.[11][13][14] In that year Glaxo restructured is R&D operation, cutting
about 10,000 jobs worldwide, closing its research and development facility in
Beckenham, Kent, which was formerly Wellcome's principal research and
development facility in the United Kingdom, and opening a Medicines Research
Centre at Stevenage in England[15][16][17] Also in that year, Glaxo Wellcome
acquired the California-based Affymax, a leader in the field ofcombinatorial
chemistry.[18] Valtrex (valaciclovir) was launched as an anti-herpes successor to
Zovirax (acyclovir).
ACQUISITION OF